To determine the factors predicting non-alcoholic steatohepatitis (NASH) and advanced fibrosis in patients with non-alcoholic fatty liver disease (NAFLD).
Methodology
All patients aged >18 years and having a fatty liver on abdominal ultrasound (US), presenting from January 2011 to January 2017, were included. A liver biopsy was performed on all the patients.
Results
Of 96 patients undergoing liver biopsy for non-alcoholic fatty liver disease (NAFLD), 76 (79.2%) were men. On liver US, diffuse fatty liver (DFL) was noted in 68 (70.8%) patients. Liver biopsy showed non-alcoholic steatohepatitis (NASH) in 78 (81.3%) patients. Factors associated with NASH were male gender, body mass index (BMI) > 27 kg/m2, DFL and raised alanine aminotransferase (ALT). A GULAB score (based on gender, US liver findings, lipid (fasting) levels, ALT level and BMI) of ≥5 predicted NASH with 82.05% sensitivity. Factors associated with advanced fibrosis in NAFLD were age >40 years, diabetes mellitus, AST/ALT ratio > 1 and raised GGT.
Conclusion
NASH is common in patients with male gender, high BMI, DFL on liver US, raised ALT and GULAB score ≥5.
ByrneCDTargherG. NAFLD: a multisystem disease. J Hepatol2015; 62: S47–64.
2.
ChalasaniNYounossiZLavineJEet al.The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological association. Hepatology2012; 55: 2005–2023.
3.
CalzadillaBLAdamsLA. The natural course of non-alcoholic fatty liver disease. Int J Mol Sci2016; 20: 17–17.
4.
LoombaRSanyalAJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol2013; 10: 686–690.
5.
TargherGChoncholMZoppiniGet al.Risk of chronic kidney disease in patients with non-alcoholic fatty liver disease: Is there a link?J Hepatol2011; 54: 1020–1029.
6.
BaffyG. Hepatocellular carcinoma in non-alcoholic fatty liver disease: epidemiology, pathogenesis and prevention. J Clin Transl Hepatol2013; 1: 131–137.
7.
ZezosPRennerEL. Liver transplantation and non-alcoholic fatty liver disease. World J Gastroenterol2014; 20: 15532–15538.
8.
SanyalAJNon-alcoholic fatty liver disease. In: YamadaT (ed). Textbook of Gastroenterology, 5th ed. New Jersey: Wiley-Blackwell, 2009, pp. 2274–2274.
9.
NeumanMGCohenLBNanauRM. Biomarkers in nonalcoholic fatty liver disease. Can J Gastroenterol Hepatol2014; 28: 607–618.
10.
SingalAKCharltonMTransplantation for nonalcoholic steatohepatitis. In: BusuttilRWKlintmalmGBG (eds). Transplantation of the liver, 3rd ed. Philadelphia, PA: Elsevier Saunders, 2015, pp. 252–252.
11.
StålP. Liver fibrosis in non-alcoholic fatty liver disease - diagnostic challenge with prognostic significance. World J Gastroenterol2015; 21: 11077–11087.
12.
BuzzettiELombardiRDe LucaLet al.Noninvasive assessment of fibrosis in patients with nonalcoholic fatty liver disease. Int J Endocrinol2015; 2015: 343828–343828.
13.
PanJJFallonMB. Gender and racial differences in nonalcoholic fatty liver disease. World J Hepatol2014; 6: 274–83.
14.
VermaSJensenDHartJet al.Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD). Liver Int2013; 33: 1398–1405.
15.
RehaJLLeeSHofmannLJ. Prevalence and predictors of nonalcoholic steatohepatitis in obese patients undergoing bariatric surgery: a department of defense experience. Am Surg2014; 80: 595–599.
16.
SekoYSumidaYTanakaSet al.Serum alanine aminotransferase predicts the histological course of non-alcoholic steatohepatitis in Japanese patients. Hepatol Res2015; 45: 53–61.
17.
LoomisAKKabadiSPreissDet al.Body mass index and risk of nonalcoholic fatty liver disease: Two electronic health record prospective studies. J Clin Endocrinol Metab2016; 101: 945–952.
18.
ArgoCKNorthupPGAl-OsaimiAMet al.Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J Hepatol2009; 51: 371–379.
19.
JúniorWSNonino-BorgesCB. Clinical predictors of different grades of nonalcoholic fatty liver disease. Obes Surg2012; 22: 248–252.
20.
McPhersonSStewartSFHendersonEet al.Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut2010; 59: 1265–1269.
21.
PraveenrajPGomesRMKumarSet al.Prevalence and predictors of non-alcoholic fatty liver disease in morbidly obese south Indian patients undergoing bariatric surgery. Obes Surg2015; 25: 2078–2087.
22.
PuchakayalaBKVermaSKanwarPet al.Histopatho-logical differences utilizing the nonalcoholic fatty liver disease activity score criteria in diabetic (type 2 diabetes mellitus) and non-diabetic patients with nonalcoholic fatty liver disease. World J Hepatol2015; 7: 2610–2618.
23.
SumidaYYonedaMHyogoHet al.Japan study group of nonalcoholic fatty liver disease (JSG-NAFLD). A simple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease. J Gastroenterol2011; 46: 257–268.
24.
AntyRIannelliAPatourauxSet al.A new composite model including metabolic syndrome, alanine aminotransferase and cytokeratin-18 for the diagnosis of non-alcoholic steatohepatitis in morbidly obese patients. Aliment Pharmacol Ther2010; 32: 1315–1322.
25.
YounossiZMPageSRafiqNet al.A biomarker panel for non-alcoholic steatohepatitis (NASH) and NASH-related fibrosis. Obes Surg2011; 2: 431–439.
